Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: Development and simulation process in Wistar rats

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Kapanigowda, Usha Ganganahalli ^a   Nagaraja, Sree Harsha ^b   Ramaiah, Balakeshwa ^a   Boggarapu, Prakash Rao ^a  

^a KARNATAKA COLLEGE OF PHARMACY   (India)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Franz cells; Ocular pharmacokinetic; Release kinetics; Simulation; Superimposition

Indexed keywords

CHITOSAN DERIVATIVE; GANCICLOVIR; MICROSPHERE; ANTIVIRUS AGENT; CHITOSAN; DELAYED RELEASE FORMULATION; EYE DROPS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; EMULSION; ENCAPSULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MAXIMUM PLASMA CONCENTRATION; MIC90; MICROPHOTOGRAPHY; NONHUMAN; PROCESS OPTIMIZATION; RAT; RETINA; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; FEMALE; MALE; MEDICINAL CHEMISTRY; WISTAR RAT;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; FEMALE; GANCICLOVIR; MALE; MICROSPHERES; OPHTHALMIC SOLUTIONS; RATS; RATS, WISTAR;

EID: 84945488525     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-015-0132-7     Document Type: Article

References (39)

1. Sahin A, Hamrah P. Acute herpetic keratitis: what is the role for ganciclovir ophthalmic gel? Ophthalmol Eye Dis. 2012;4:23-4.
2. Lin T, Gong L, Sun X, Zhao N, Chen W, Yuan H, et al. Effectiveness and safety of 0.15 % ganciclovir in situ ophthalmic gel for herpes simplex keratitis-a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Drug Des Deve Ther. 2013;7:361-8.
3. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. Antivir Chem Chemother. 2010;21:53-70.
4. Moshfeghi AA, Peyman GA. Micro- and nanoparticulates. Adv Drug Deliv Rev. 2005;57:2047-52.
5. Young S, Morlet N, Besen G, Wiley CA, Jones P, Gold J, et al. High-dose (2000-μg) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmol. 1998;105:1404-10.
6. Janoria KG, Mitra AK. Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophillic prodrug (GCV-monobutyrate) from PLGA microspheres. Int J Pharm. 2007;338:133-41.
7. Charles NC, Steiner GC. Ganciclovir intraocular implant. A clinicopathologic study. Ophthalmol. 1996;103(3):416-21.
8. Teoh SC, Ou X, Lim TH. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis:effeicacy of a low-volume, intermediate-dose regimen. Ophthalmol. 2012;119:588-95.
9. Shah P, Jogani V, Mishra P, Mishra AK, Bagchi T, Misra A. Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. L Pharm Sci. 2007;96:2710-22.
10. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55:1451-63.
11. Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463-9.
12. Tamboli V, Mishra GP, Mitra K. Biodegradable polymers for ocular drug delivery, in Mitra AK: Advances in Ocular Drug Delivery, Research signpost, Kerala. 2012. p. 65-86.
13. Ye T, Yuan K, Zhang W, Song S, Chen F, Yang X, et al. Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci. 2013;8:207-17.
14. Badawi AA, El-Laithy HM, El Qidra RK. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31:1040-9.
15. Calvo P, Vila-Jato JL, Alonso MAJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm. 1997;153:41-50.
16. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001;224:159-68.
17. Di Colo G, Zambito Y, Brugalassi S, Serafinin A, Saettone MF. Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts on poly(ethylene oxide). Int J Pharm. 2002;248:115-22.
18. Genta I, Conti B, Perugini P, Pavanetto F, Spadaro A, Puglisi G. Bioadhesive microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol. 1997;49:737-42.
19. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-60.
20. Campanero MA, Sadaba B, Garcia-Quetglas E, Azanza JR. Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J Chromatogr B. 1998;706:311-7.
21. Park J, Jin H, Kim D, Chug S, Shim W, Shim C. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm. 2013;441:562-9.
22. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm. 2001;229:29-36.
23. Dillen K, Vandervoort J, Mooter GV, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm. 2006;314:72-82.
24. Gibaud S, Al Awwadi NJ, Ducki C, Astier A. Poly(-caprolactone) and eudragit microparticles containing fludracortisones acetate. Int J Pharm. 2004;269:491-508.
25. Huang J, Wigent RJ, Bentzley CM, Schwartz JB. Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery effect of drug loading on release kinetics. Int J Pharm. 2006;319:44-54.
26. Li X, Nie S, Kong J, Li N, Ju C, Pan W. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363:177-82.
27. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm. 2004;57:207-12.
28. Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J. 2007;9(3):E371-7.
29. Bhatta RS, Chandasana H, Chhonker YS, Rathi C, Kumar D, Mitra K, et al. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. Int J Pharm. 2012;432:105-12.
30. Elgadir MA, Uddin MS, Ferdous S, Adam A, Chowdhary AJK, Sarker MZI. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: A review. J Food Drug Anal. 2014, http://dx.doi.org/ 10.1016/j.jfda.2014.10.008
31. Mathew ST, Devi SG, Sandhya KV. Formulation and evaluation of ketorolac tromethamine-loaded albumin microspheres for potential intramuscular administration. AAPS PharmSciTech. 2007;8(1):E1-9.
32. Kumbar SG, Kulkarni AR, Aminabhavi M. Crosslinked chitosan microspheres for encapsulation of diclofenac sodium: effect of crosslinking agent. J Microencapsul. 2002;19(2):173-80.
33. Silva CM, Ribeiro AJ, Figueiredo M, Ferreira D, Veiga F. Microencapsulation of hemoglobin in chitosan-coated alginate microspheres prepared by emulsification/internal gelation. AAPS J. 2006;7(4):E903-13.
34. Thakkar H, Sharma RK, Mishra AK, Chuttani K, Murthy RR. Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech. 2005;6(1):E65-73.
35. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech. 2011;12(4):1087-101.
36. Jose S, Fangueiro JF, Smitha J, Cinu TA, Chacko AJ, Premaletha K, et al. Predictive modeling of insulin release profile from cross-linked chitosan microspheres. Eur J Med Chem. 2013;60:249-53.
37. Martinac A, Filipovic-Grcic J, Voinovich D, Perissutti B, Francechinis E. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm. 2005;291:69-77.
38. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16:107-23.
39. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379:131-8.